CEO Renée Aguiar-Lucander (Calliditas)

New­ly Nas­daq-list­ed Cal­lid­i­tas surges af­ter lead kid­ney drug hits pri­ma­ry end­point

Cal­lid­i­tas still hasn’t proven to pa­tients that their kid­ney drug has long-term ben­e­fits, but the com­pa­ny says they’ve seen more than enough to go to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.